{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T14:20:17Z","timestamp":1779891617077,"version":"3.53.1"},"reference-count":152,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2020,8,31]],"date-time":"2020-08-31T00:00:00Z","timestamp":1598832000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Tuberculosis remains the world\u2019s top infectious killer: it caused a total of 1.5 million deaths and 10 million people fell ill with TB in 2018. Thanks to TB diagnosis and treatment, mortality has been falling in recent years, with an estimated 58 million saved lives between 2000 and 2018. However, the emergence of multidrug-resistant (MDR) and extensively drug-resistant (XDR) Mtb strains is a major concern that might reverse this progress. Therefore, the development of new drugs acting upon novel mechanisms of action is a high priority in the global health agenda. With the approval of bedaquiline, which targets mycobacterial energy production, and delamanid, which targets cell wall synthesis and energy production, the energy-metabolism in Mtb has received much attention in the last decade as a potential target to investigate and develop new antimycobacterial drugs. In this review, we describe potent anti-mycobacterial agents targeting the energy-metabolism at different steps with a special focus on structure-activity relationship (SAR) studies of the most advanced compound classes.<\/jats:p>","DOI":"10.3390\/ph13090227","type":"journal-article","created":{"date-parts":[[2020,8,31]],"date-time":"2020-08-31T11:53:49Z","timestamp":1598874829000},"page":"227","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["SAR Analysis of Small Molecules Interfering with Energy-Metabolism in Mycobacterium tuberculosis"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0458-3349","authenticated-orcid":false,"given":"Federico","family":"Appetecchia","sequence":"first","affiliation":[{"name":"Department of Chemistry and Technologies of Drug, Sapienza University of Rome, piazzale A. Moro 5, 00185 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6562-7686","authenticated-orcid":false,"given":"Sara","family":"Consalvi","sequence":"additional","affiliation":[{"name":"Department of Chemistry and Technologies of Drug, Sapienza University of Rome, piazzale A. Moro 5, 00185 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7967-091X","authenticated-orcid":false,"given":"Cristina","family":"Scarpecci","sequence":"additional","affiliation":[{"name":"Department of Chemistry and Technologies of Drug, Sapienza University of Rome, piazzale A. Moro 5, 00185 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariangela","family":"Biava","sequence":"additional","affiliation":[{"name":"Department of Chemistry and Technologies of Drug, Sapienza University of Rome, piazzale A. Moro 5, 00185 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7466-8861","authenticated-orcid":false,"given":"Giovanna","family":"Poce","sequence":"additional","affiliation":[{"name":"Department of Chemistry and Technologies of Drug, Sapienza University of Rome, piazzale A. Moro 5, 00185 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,8,31]]},"reference":[{"key":"ref_1","unstructured":"WHO (2020, July 08). Global tuberculosis report. Available online: http:\/\/www.who.int\/tb\/publications\/global_report\/en\/."},{"key":"ref_2","unstructured":"Pipeline (2020, July 09). Working Group for New TB Drugs. Available online: https:\/\/www.newtbdrugs.org\/pipeline\/clinical."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"112390","DOI":"10.1016\/j.ejmech.2020.112390","article-title":"MmpL3 inhibitors as antituberculosis drugs","volume":"200","author":"Shao","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1021\/acsmedchemlett.9b00204","article-title":"Novel pyrazole-containing compounds active against Mycobacterium tuberculosis","volume":"10","author":"Poce","year":"2019","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.ejmech.2017.12.075","article-title":"In vivo potent BM635 analogue with improved drug-like properties","volume":"145","author":"Poce","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"7993","DOI":"10.1073\/pnas.1700062114","article-title":"MmpL3 is the flippase for mycolic acids in mycobacteria","volume":"114","author":"Xu","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.drudis.2016.09.014","article-title":"Structural studies of Mycobacterium tuberculosis DprE1 interacting with its inhibitors","volume":"22","author":"Piton","year":"2017","journal-title":"Drug Discov. Today"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s13065-018-0441-2","article-title":"Decaprenyl-phosphoryl-ribose 2\u2032-epimerase (DprE1): Challenging target for antitubercular drug discovery","volume":"12","author":"Gawad","year":"2018","journal-title":"Chem. Cent. J."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Christophe, T., Jackson, M., Jeon, H.K., Fenistein, D., Contreras-Dominguez, M., Kim, J., Genovesio, A., Carralot, J.-P., Ewann, F., and Kim, E.H. (2009). High content screening identifies decaprenyl-phosphoribose 2\u2032 epimerase as a target for intracellular antimycobacterial inhibitors. PLoS Pathog., 5.","DOI":"10.1371\/journal.ppat.1000645"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"11565","DOI":"10.1073\/pnas.1302114110","article-title":"Diarylcoumarins inhibit mycolic acid biosynthesis and kill Mycobacterium tuberculosis by targeting FadD","volume":"110","author":"Stanley","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"6126","DOI":"10.2174\/0929867311209066126","article-title":"Advances in mycobacterial isocitrate lyase targeting and inhibitors","volume":"19","year":"2012","journal-title":"Curr. Med. Chem."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/ddr.21498","article-title":"Bedaquiline and delamanid in the treatment of multidrug-resistant tuberculosis: Promising but challenging","volume":"80","author":"Li","year":"2019","journal-title":"Drug Dev. Res."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Bald, D., Villellas, C., Lu, P., and Koul, A. (2017). Targeting energy metabolism in Mycobacterium tuberculosis, a New paradigm in antimycobacterial drug discovery. mBio, 8.","DOI":"10.1128\/mBio.00272-17"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1016\/S0140-6736(19)30308-3","article-title":"Tuberculosis","volume":"393","author":"Furin","year":"2019","journal-title":"Lancet"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Cook, G.M., Hards, K., Dunn, E., Heikal, A., Nakatani, Y., Greening, C., Crick, D.C., Fontes, F.L., Pethe, K., and Hasenoehrl, E. (2017). Oxidative phosphorylation as a target space for tuberculosis: Success, caution, and future directions. Microbiol. Spectr., 5.","DOI":"10.1128\/microbiolspec.TBTB2-0014-2016"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Cook, G.M., Hards, K., Vilch\u00e8ze, C., Hartman, T., and Berney, M. (2014). Energetics of respiration and oxidative phosphorylation in mycobacteria. Microbiol. Spectr., 2.","DOI":"10.1128\/microbiolspec.MGM2-0015-2013"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.3390\/molecules15031531","article-title":"Vitamin K2 in electron transport system: Are enzymes involved in vitamin K2 biosynthesis promising drug targets?","volume":"15","author":"Kurosu","year":"2010","journal-title":"Molecules"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"5099","DOI":"10.1039\/C7RA12950E","article-title":"Menaquinone biosynthesis inhibition: A review of advancements toward a new antibiotic mechanism","volume":"8","author":"Boersch","year":"2018","journal-title":"RSC Adv."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1021\/acschembio.8b00402","article-title":"Mycobacterial MenJ: An oxidoreductase involved in menaquinone biosynthesis","volume":"13","author":"Upadhyay","year":"2018","journal-title":"ACS Chem. Biol."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Harikishore, A., Chong, S.S.M., Ragunathan, P., Bates, R.W., and Gr\u00fcber, G. (2020). Targeting the menaquinol binding loop of mycobacterial cytochrome bd oxidase. Mol. Divers.","DOI":"10.1007\/s11030-020-10034-0"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/bs.armc.2019.05.001","article-title":"Chapter Four\u2014Inhibitors of enzymes in the electron transport chain of Mycobacterium tuberculosis","volume":"Volume 52","author":"Chibale","year":"2019","journal-title":"Annual Reports in Medicinal Chemistry"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"4548","DOI":"10.1073\/pnas.0500469102","article-title":"Inhibitors of type II NADH: Menaquinone oxidoreductase represent a class of antitubercular drugs","volume":"102","author":"Weinstein","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"40165","DOI":"10.1038\/srep40165","article-title":"The mechanism of catalysis by type-II NADH:quinone oxidoreductases","volume":"7","author":"Blaza","year":"2017","journal-title":"Sci Rep."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Xu, J., Wang, B., Hu, M., Huo, F., Guo, S., Jing, W., Nuermberger, E., and Lu, Y. (2017). Primary Clofazimine and Bedaquiline Resistance among isolates from patients with multidrug-resistant tuberculosis. Antimicrob. Agents Chemother., 61.","DOI":"10.1128\/AAC.00239-17"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1021\/mp034006h","article-title":"Molecular properties of WHO essential drugs and provisional biopharmaceutical classification","volume":"1","author":"Kasim","year":"2004","journal-title":"Mol. Pharm."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.4269\/ajtmh.1974.23.1110","article-title":"Some observations on the pharmacology of clofazimine (B663)","volume":"23","author":"Banerjee","year":"1974","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"3042","DOI":"10.1128\/AAC.00260-15","article-title":"Pharmacokinetics and pharmacodynamics of clofazimine in a mouse model of tuberculosis","volume":"59","author":"Swanson","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"10276","DOI":"10.1074\/jbc.M110.200501","article-title":"Reduction of clofazimine by mycobacterial type 2 NADH:quinone oxidoreductase: A pathway for the generation of bactericidal levels of reactive oxygen species","volume":"286","author":"Yano","year":"2011","journal-title":"J. Biol. Chem."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"4545","DOI":"10.3390\/molecules17044545","article-title":"Systematic evaluation of structure-activity relationships of the riminophenazine class and discovery of a C2 pyridylamino series for the treatment of multidrug-resistant tuberculosis","volume":"17","author":"Liu","year":"2012","journal-title":"Molecules"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"8409","DOI":"10.1021\/jm300828h","article-title":"Identification of less lipophilic riminophenazine derivatives for the treatment of drug-resistant tuberculosis","volume":"55","author":"Zhang","year":"2012","journal-title":"J. Med. Chem."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"4380","DOI":"10.3390\/molecules19044380","article-title":"Synthesis and biological evaluation of novel 2-methoxypyridylamino-substituted riminophenazine derivatives as antituberculosis agents","volume":"19","author":"Zhang","year":"2014","journal-title":"Molecules"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"5185","DOI":"10.1128\/AAC.00699-11","article-title":"Clofazimine analogs with efficacy against experimental tuberculosis and reduced potential for accumulation","volume":"55","author":"Lu","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Xu, J., Wang, B., Fu, L., Zhu, H., Guo, S., Huang, H., Yin, D., Zhang, Y., and Lu, Y. (2019). In vitro and in vivo activities of the riminophenazine TBI-166 against Mycobacterium tuberculosis. Antimicrob. Agents Chemother., 63.","DOI":"10.1128\/AAC.02155-18"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"8298","DOI":"10.1073\/pnas.1205651109","article-title":"Generation of quinolone antimalarials targeting the Plasmodium falciparum mitochondrial respiratory chain for the treatment and prophylaxis of malaria","volume":"109","author":"Biagini","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/j.biopha.2014.10.007","article-title":"Quinoline: A promising antitubercular target","volume":"68","author":"Keri","year":"2014","journal-title":"Biomed. Pharmacother."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"3703","DOI":"10.1021\/acs.jmedchem.6b01718","article-title":"Rational design, synthesis, and biological evaluation of heterocyclic quinolones targeting the respiratory chain of Mycobacterium tuberculosis","volume":"60","author":"Hong","year":"2017","journal-title":"J. Med. Chem."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1021\/ml300134b","article-title":"Quinolinyl Pyrimidines: Potent inhibitors of NDH-2 as a novel class of anti-TB agents","volume":"3","author":"Shirude","year":"2012","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"3238","DOI":"10.1016\/j.bmc.2010.03.021","article-title":"The anti-cancer, anti-inflammatory and tuberculostatic activities of a series of 6,7-substituted-5,8-quinolinequinones","volume":"18","author":"Mulchin","year":"2010","journal-title":"Bioorganic Med. Chem."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1002\/anie.201800260","article-title":"small molecules targeting Mycobacterium tuberculosis Type II NADH dehydrogenase exhibit antimycobacterial activity","volume":"57","author":"Harbut","year":"2018","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1021\/acsinfecdis.7b00275","article-title":"2-Mercapto-quinazolinones as inhibitors of type II NADH dehydrogenase and Mycobacterium tuberculosis: Structure-activity relationships, mechanism of action and absorption, distribution, metabolism, and excretion characterization","volume":"4","author":"Murugesan","year":"2018","journal-title":"ACS Infect. Dis."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Ioerger, T.R., O\u2019Malley, T., Liao, R., Guinn, K.M., Hickey, M.J., Mohaideen, N., Murphy, K.C., Boshoff, H.I.M., Mizrahi, V., and Rubin, E.J. (2013). Identification of new drug targets and resistance mechanisms in Mycobacterium tuberculosis. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0075245"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1128\/JB.186.4.928-937.2004","article-title":"Inhibition of membrane-bound methane monooxygenase and ammonia monooxygenase by diphenyliodonium: Implications for electron transfer","volume":"186","author":"Shiemke","year":"2004","journal-title":"J. Bacteriol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/ja.2013.111","article-title":"A secondary mode of action of polymyxins against Gram-negative bacteria involves the inhibition of NADH-quinone oxidoreductase activity","volume":"67","author":"Deris","year":"2014","journal-title":"J. Antibiot."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"11521","DOI":"10.1038\/s41598-017-11575-5","article-title":"Diphenyleneiodonium chloride (DPIC) displays broad-spectrum bactericidal activity","volume":"7","author":"Pandey","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.ejmech.2017.10.010","article-title":"Broad activity of diphenyleneiodonium analogues against Mycobacterium tuberculosis, malaria parasites and bacterial pathogens","volume":"148","author":"Nguyen","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Gong, H., Li, J., Xu, A., Tang, Y., Ji, W., Gao, R., Wang, S., Yu, L., Tian, C., and Li, J. (2018). An electron transfer path connects subunits of a mycobacterial respiratory supercomplex. Science, 362.","DOI":"10.1126\/science.aat8923"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"4970","DOI":"10.1038\/s41467-019-12956-2","article-title":"Plasticity of the Mycobacterium tuberculosis respiratory chain and its impact on tuberculosis drug development","volume":"10","author":"Beites","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Abrahams, K.A., Cox, J.A.G., Spivey, V.L., Loman, N.J., Pallen, M.J., Constantinidou, C., Fern\u00e1ndez, R., Alemparte, C., Remui\u00f1\u00e1n, M.J., and Barros, D. (2012). Identification of novel imidazo[1,2-a]pyridine inhibitors targeting M. tuberculosis QcrB. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0052951"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1021\/acs.jmedchem.6b01358","article-title":"Discovery of imidazo[1,2-a]pyridine ethers and squaramides as selective and potent inhibitors of mycobacterial adenosine triphosphate (ATP) synthesis","volume":"60","author":"Tantry","year":"2017","journal-title":"J. Med. Chem."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"6962","DOI":"10.1128\/AAC.03486-14","article-title":"Respiratory flexibility in response to inhibition of cytochrome C oxidase in Mycobacterium tuberculosis","volume":"58","author":"Arora","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1038\/nm.3262","article-title":"Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis","volume":"19","author":"Pethe","year":"2013","journal-title":"Nat. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.2174\/1389557517666170220152651","article-title":"Phenothiazine: A better scaffold against tuberculosis","volume":"18","author":"Sellamuthu","year":"2018","journal-title":"Mini Rev. Med. Chem."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.ejmech.2017.05.021","article-title":"Synthesis and structure-activity relationships of novel fused ring analogues of Q203 as antitubercular agents","volume":"136","author":"Kang","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.ejmech.2016.09.082","article-title":"Synthesis and structure-activity studies of side chain analogues of the anti-tubercular agent, Q203","volume":"125","author":"Kang","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.ejmech.2019.06.038","article-title":"Design, synthesis and biological activity of N-(2-phenoxy)ethyl imidazo[1,2-a]pyridine-3-carboxamides as new antitubercular agents","volume":"178","author":"Wang","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.bmc.2019.01.022","article-title":"Design, synthesis and antimycobacterial activity of less lipophilic Q203 derivatives containing alkaline fused ring moieties","volume":"27","author":"Wang","year":"2019","journal-title":"Bioorganic Med. Chem."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Li, L., Li, Z., Liu, M., Shen, W., Wang, B., Guo, H., and Lu, Y. (2015). Design, synthesis and antimycobacterial activity of novel imidazo[1,2-a]pyridine amide-cinnamamide hybrids. Molecules, 21.","DOI":"10.3390\/molecules21010049"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ejmech.2018.12.071","article-title":"Synthesis and antitubercular evaluation of reduced lipophilic imidazo[1,2-a]pyridine-3-carboxamide derivatives","volume":"165","author":"Wang","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1021\/id500008t","article-title":"Putting tuberculosis (TB) to rest: Transformation of the sleep aid, ambien, and \u201canagrams\u201d generated potent antituberculosis agents","volume":"1","author":"Moraski","year":"2015","journal-title":"ACS Infect. Dis."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1021\/acsmedchemlett.5b00176","article-title":"Design, synthesis, and biological evaluation of pyrazolo[1,5-a]pyridine-3-carboxamides as novel antitubercular agents","volume":"6","author":"Tang","year":"2015","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1021\/acsinfecdis.5b00154","article-title":"Arrival of imidazo[2,1-b]thiazole-5-carboxamides: Potent anti-tuberculosis agents that target QcrB","volume":"2","author":"Moraski","year":"2016","journal-title":"ACS Infect. Dis."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Moraski, G.C., Deboos\u00e8re, N., Marshall, K.L., Weaver, H.A., Vandeputte, A., Hastings, C., Woolhiser, L., Lenaerts, A.J., Brodin, P., and Miller, M.J. (2020). Intracellular and in vivo evaluation of imidazo[2,1-b]thiazole-5-carboxamide anti-tuberculosis compounds. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0227224"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1021\/acs.biochem.8b00975","article-title":"Target engagement and binding mode of an antituberculosis drug to its bacterial target deciphered in whole living cells by NMR","volume":"58","author":"Bouvier","year":"2019","journal-title":"Biochemistry"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1056\/NEJMc1913327","article-title":"Telacebec (Q203), a new antituberculosis agent","volume":"382","author":"Dawson","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/cmdc.201200428","article-title":"Fueling open-source drug discovery: 177 small-molecule leads against tuberculosis","volume":"8","author":"Ballell","year":"2013","journal-title":"ChemMedChem"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1039\/C6MD00236F","article-title":"SAR and identification of 2-(quinolin-4-yloxy)acetamides as Mycobacterium tuberculosis cytochrome bc1 inhibitors","volume":"7","author":"Phummarin","year":"2016","journal-title":"Medchemcomm"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1021\/acsmedchemlett.5b00324","article-title":"2-(Quinolin-4-yloxy)acetamides are active against drug-susceptible and drug-resistant Mycobacterium tuberculosis strains","volume":"7","author":"Pissinate","year":"2016","journal-title":"ACS Med. Chem. Lett"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.ejmech.2016.11.048","article-title":"New insights into the SAR and drug combination synergy of 2-(quinolin-4-yloxy)acetamides against Mycobacterium tuberculosis","volume":"126","author":"Giacobbo","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"6709","DOI":"10.1021\/acs.jmedchem.6b00245","article-title":"Searching for new leads for tuberculosis: Design, synthesis, and biological evaluation of novel 2-quinolin-4-yloxyacetamides","volume":"59","author":"Pitta","year":"2016","journal-title":"J. Med. Chem."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"112179","DOI":"10.1016\/j.ejmech.2020.112179","article-title":"Design, synthesis, and evaluation of new 2-(quinoline-4-yloxy)acetamide-based antituberculosis agents","volume":"192","author":"Borsoi","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.ijantimicag.2017.08.023","article-title":"Activity of 2-(quinolin-4-yloxy)acetamides in Mycobacterium tuberculosis clinical isolates and identification of their molecular target by whole-genome sequencing","volume":"51","author":"Subtil","year":"2018","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"6592","DOI":"10.1021\/acs.jmedchem.8b00172","article-title":"Identification of morpholino thiophenes as novel Mycobacterium tuberculosis inhibitors, targeting QcrB","volume":"61","author":"Cleghorn","year":"2018","journal-title":"J. Med. Chem."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ejmech.2016.09.030","article-title":"Pyrazolo[1,5-a]pyridine-3-carboxamide hybrids: Design, synthesis and evaluation of anti-tubercular activity","volume":"125","author":"Lu","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Foo, C.S., Lupien, A., Kienle, M., Vocat, A., Benjak, A., Sommer, R., Lamprecht, D.A., Steyn, A.J.C., Pethe, K., and Piton, J. (2018). Arylvinylpiperazine amides, a new class of potent inhibitors targeting QcrB of Mycobacterium tuberculosis. mBio, 9.","DOI":"10.1128\/mBio.01276-18"},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Harrison, G.A., Mayer Bridwell, A.E., Singh, M., Jayaraman, K., Weiss, L.A., Kinsella, R.L., Aneke, J.S., Flentie, K., Schene, M.E., and Gaggioli, M. (2019). Identification of 4-amino-thieno[2,3-d]pyrimidines as QcrB inhibitors in Mycobacterium tuberculosis. mSphere, 4.","DOI":"10.1128\/mSphere.00606-19"},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Lupien, A., Foo, C.S.-Y., Savina, S., Vocat, A., Piton, J., Monakhova, N., Benjak, A., Lamprecht, D.A., Steyn, A.J.C., and Pethe, K. (2020). New 2-Ethylthio-4-methylaminoquinazoline derivatives inhibiting two subunits of cytochrome bc1 in Mycobacterium tuberculosis. PLoS Pathog., 16.","DOI":"10.1371\/journal.ppat.1008270"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"16281","DOI":"10.1039\/C9NJ03462E","article-title":"Structural modification of zolpidem led to potent antimicrobial activity in imidazo[1,2-a]pyridine\/pyrimidine-1,2,3-triazoles","volume":"43","author":"Reddyrajula","year":"2019","journal-title":"New J. Chem."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"7659","DOI":"10.1038\/ncomms8659","article-title":"Lansoprazole is an antituberculous prodrug targeting cytochrome bc1","volume":"6","author":"Rybniker","year":"2015","journal-title":"Nat. Commun."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"e4035","DOI":"10.1002\/bmc.4035","article-title":"Lansoprazole-sulfide, pharmacokinetics of this promising anti-tuberculous agent","volume":"31","author":"Mdanda","year":"2017","journal-title":"Biomed. Chromatogr."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"7426","DOI":"10.1073\/pnas.1706139114","article-title":"Exploiting the synthetic lethality between terminal respiratory oxidases to kill Mycobacterium tuberculosis and clear host infection","volume":"114","author":"Kalia","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"258","DOI":"10.7164\/antibiotics.40.258","article-title":"The aurachins, new quinoline antibiotics from myxobacteria: Production, physico-chemical and biological properties","volume":"40","author":"Kunze","year":"1987","journal-title":"J. Antibiot."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.3762\/bjoc.9.176","article-title":"Synthesis and biological activities of the respiratory chain inhibitor aurachin D and new ring versus chain analogues","volume":"9","author":"Li","year":"2013","journal-title":"Beilstein J. Org. Chem."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"10333","DOI":"10.1038\/srep10333","article-title":"The cytochrome bd-type quinol oxidase is important for survival of Mycobacterium smegmatis under peroxide and antibiotic-induced stress","volume":"5","author":"Lu","year":"2015","journal-title":"Sci. Rep."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1038\/s41598-018-20989-8","article-title":"The anti-mycobacterial activity of the cytochrome bcc inhibitor Q203 can be enhanced by small-molecule inhibition of cytochrome bd","volume":"8","author":"Lu","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Sukheja, P., Kumar, P., Mittal, N., Li, S.-G., Singleton, E., Russo, R., Perryman, A.L., Shrestha, R., Awasthi, D., and Husain, S. (2017). A novel small-molecule inhibitor of the Mycobacterium tuberculosis demethylmenaquinone methyltransferase MenG is bactericidal to both growing and nutritionally deprived persister cells. mBio, 8.","DOI":"10.1128\/mBio.02022-16"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"11262","DOI":"10.1074\/jbc.M117.784959","article-title":"The uniqueness of subunit \u03b1 of mycobacterial F-ATP synthases: An evolutionary variant for niche adaptation","volume":"292","author":"Ragunathan","year":"2017","journal-title":"J. Biol. Chem."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"4206","DOI":"10.1073\/pnas.1817615116","article-title":"The structure of the catalytic domain of the ATP synthase from Mycobacterium smegmatis is a target for developing antitubercular drugs","volume":"116","author":"Zhang","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"e1500106","DOI":"10.1126\/sciadv.1500106","article-title":"Structure of the mycobacterial ATP synthase Fo rotor ring in complex with the anti-TB drug bedaquiline","volume":"1","author":"Preiss","year":"2015","journal-title":"Sci. Adv."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.pbiomolbio.2019.11.006","article-title":"Unique structural and mechanistic properties of mycobacterial F-ATP synthases: Implications for drug design","volume":"152","author":"Kamariah","year":"2020","journal-title":"Prog. Biophys. Mol. Biol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/j.bbabio.2014.01.022","article-title":"ATP synthase in mycobacteria: Special features and implications for a function as drug target","volume":"1837","author":"Lu","year":"2014","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1126\/science.1106753","article-title":"A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis","volume":"307","author":"Andries","year":"2005","journal-title":"Science"},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Sarathy, J.P., Gruber, G., and Dick, T. (2019). Re-understanding the mechanisms of action of the anti-mycobacterial drug bedaquiline. Antibiotics, 8.","DOI":"10.3390\/antibiotics8040261"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"7326","DOI":"10.1073\/pnas.1803723115","article-title":"Ionophoric effects of the antitubercular drug bedaquiline","volume":"115","author":"Hards","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.4155\/fmc.11.79","article-title":"Diarylquinolines, synthesis pathways and quantitative structure--activity relationship studies leading to the discovery of TMC","volume":"3","author":"Guillemont","year":"2011","journal-title":"Future Med. Chem."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1586\/14787210.2014.870884","article-title":"The early bactericidal activity of antituberculosis drugs","volume":"12","author":"Diacon","year":"2014","journal-title":"Expert Rev. Anti Infect. Ther."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/S2213-2600(18)30235-2","article-title":"Effect of bedaquiline on mortality in South African patients with drug-resistant tuberculosis: A retrospective cohort study","volume":"6","author":"Schnippel","year":"2018","journal-title":"Lancet Respir. Med."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/S1473-3099(19)30168-9","article-title":"Bedaquiline and delamanid in combination for treatment of drug-resistant tuberculosis","volume":"19","author":"Mohr","year":"2019","journal-title":"Lancet Infect. Dis."},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Jones, J., Mudaly, V., Voget, J., Naledi, T., Maartens, G., and Cohen, K. (2019). Adverse drug reactions in South African patients receiving bedaquiline-containing tuberculosis treatment: An evaluation of spontaneously reported cases. BMC Infect. Dis., 19.","DOI":"10.1186\/s12879-019-4197-7"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.tube.2019.06.005","article-title":"A structural insight of bedaquiline for the cardiotoxicity and hepatotoxicity","volume":"117","author":"Patel","year":"2019","journal-title":"Tuberculosis"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.bmc.2014.12.060","article-title":"Novel, potent, orally bioavailable and selective mycobacterial ATP synthase inhibitors that demonstrated activity against both replicating and non-replicating M. tuberculosis","volume":"23","author":"Singh","year":"2015","journal-title":"Bioorganic Med. Chem."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1016\/j.bmc.2009.02.026","article-title":"Design, synthesis, biological evaluation and molecular modelling studies of novel quinoline derivatives against Mycobacterium tuberculosis","volume":"17","author":"Upadhayaya","year":"2009","journal-title":"Bioorganic Med. Chem."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"4681","DOI":"10.1016\/j.bmc.2009.04.069","article-title":"Design, synthesis and biological evaluation of novel triazole, urea and thiourea derivatives of quinoline against Mycobacterium tuberculosis","volume":"17","author":"Upadhayaya","year":"2009","journal-title":"Bioorganic Med. Chem."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1039\/b924102g","article-title":"Conformationally-constrained indeno[2,1-c]quinolines\u2014A new class of anti-mycobacterial agents","volume":"8","author":"Upadhayaya","year":"2010","journal-title":"Org. Biomol. Chem."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"5661","DOI":"10.1039\/c0ob00445f","article-title":"Synthesis and structure of azole-fused indeno[2,1-c]quinolines and their anti-mycobacterial properties","volume":"8","author":"Upadhayaya","year":"2010","journal-title":"Org. Biomol. Chem."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1016\/j.ejmech.2010.01.024","article-title":"Novel quinoline and naphthalene derivatives as potent antimycobacterial agents","volume":"45","author":"Upadhayaya","year":"2010","journal-title":"Eur. J. Med. Chem."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/cmdc.201600441","article-title":"Structural simplification of bedaquiline: The discovery of 3-(4-(N,N-dimethylaminomethyl)phenyl)quinoline-derived antitubercular lead compounds","volume":"12","author":"He","year":"2017","journal-title":"ChemMedChem"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1021\/acsmedchemlett.7b00196","article-title":"6-Cyano analogues of bedaquiline as less lipophilic and potentially safer diarylquinolines for tuberculosis","volume":"8","author":"Tong","year":"2017","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"5190","DOI":"10.1016\/j.bmcl.2017.10.042","article-title":"Synthesis and evaluation of analogues of the tuberculosis drug bedaquiline containing heterocyclic B-ring units","volume":"27","author":"Choi","year":"2017","journal-title":"Bioorganic Med. Chem. Lett."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1016\/j.bmc.2018.02.026","article-title":"Structure-activity relationships for analogs of the tuberculosis drug bedaquiline with the naphthalene unit replaced by bicyclic heterocycles","volume":"26","author":"Sutherland","year":"2018","journal-title":"Bioorganic Med. Chem."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1016\/j.bmc.2019.02.026","article-title":"3,5-Dialkoxypyridine analogues of bedaquiline are potent antituberculosis agents with minimal inhibition of the hERG channel","volume":"27","author":"Sutherland","year":"2019","journal-title":"Bioorganic Med. Chem."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"115213","DOI":"10.1016\/j.bmc.2019.115213","article-title":"Variations in the C-unit of bedaquiline provides analogues with improved biology and pharmacology","volume":"28","author":"Sutherland","year":"2020","journal-title":"Bioorganic Med. Chem."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.bmc.2019.02.025","article-title":"Structure-activity relationships for unit C pyridyl analogues of the tuberculosis drug bedaquiline","volume":"27","author":"Blaser","year":"2019","journal-title":"Bioorganic Med. Chem."},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Sarathy, J.P., Ragunathan, P., Cooper, C.B., Upton, A.M., Gr\u00fcber, G., and Dick, T. (2020). TBAJ-876 Displays bedaquiline-like mycobactericidal potency without retaining the parental drug\u2019s uncoupler activity. Antimicrob. Agents Chemother., 64.","DOI":"10.1128\/AAC.01540-19"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"16759","DOI":"10.1038\/s41598-019-53107-3","article-title":"Disrupting coupling within mycobacterial F-ATP synthases subunit \u03b5 causes dysregulated energy production and cell wall biosynthesis","volume":"9","author":"Saw","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.tube.2017.10.008","article-title":"Screening of antitubercular compound library identifies novel ATP synthase inhibitors of Mycobacterium tuberculosis","volume":"108","author":"Kumar","year":"2018","journal-title":"Tuberculosis"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1039\/C5MD00589B","article-title":"Scaffold morphing leading to evolution of 2,4-diaminoquinolines and aminopyrazolopyrimidines as inhibitors of the ATP synthesis pathway","volume":"7","author":"Tantry","year":"2016","journal-title":"Med. Chem. Commun."},{"key":"ref_117","doi-asserted-by":"crossref","unstructured":"Hotra, A., Ragunathan, P., Ng, P.S., Seankongsuk, P., Harikishore, A., Sarathy, J.P., Saw, W.-G., Lakshmanan, U., Sae-Lao, P., and Kalia, N.P. (2020). Discovery of a novel mycobacterial F-ATP synthase inhibitor and its potency in combination with diarylquinolines. Angew. Chem. Int. Ed. Engl.","DOI":"10.1002\/anie.202002546"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1111\/febs.13715","article-title":"Deletion of a unique loop in the mycobacterial F-ATP synthase \u03b3 subunit sheds light on its inhibitory role in ATP hydrolysis-driven H(+) pumping","volume":"283","author":"Hotra","year":"2016","journal-title":"FEBS J."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"3617","DOI":"10.1021\/ja01134a045","article-title":"Experimental chemotherapy of tuberculosis. II. The synthesis of pyrazinamides and related compounds","volume":"74","author":"Kushner","year":"1952","journal-title":"J. Am. Chem. Soc."},{"key":"ref_120","doi-asserted-by":"crossref","unstructured":"Shi, W., Cui, P., Niu, H., Zhang, S., T\u00f8njum, T., Zhu, B., and Zhang, Y. (2019). Introducing RpsA point mutations \u0394438A and D123A into the chromosome of Mycobacterium tuberculosis confirms their role in causing resistance to pyrazinamide. Antimicrob. Agents Chemother., 63.","DOI":"10.1128\/AAC.02681-18"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/s41467-019-14238-3","article-title":"The molecular basis of pyrazinamide activity on Mycobacterium tuberculosis PanD","volume":"11","author":"Sun","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"823","DOI":"10.2217\/fmb.12.56","article-title":"Discovery and development of SQ109: A new antitubercular drug with a novel mechanism of action","volume":"7","author":"Sacksteder","year":"2012","journal-title":"Future Microbiol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.trsl.2020.03.007","article-title":"New tuberculosis drug targets, their inhibitors, and potential therapeutic impact","volume":"220","author":"Shetye","year":"2020","journal-title":"Transl. Res."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"6413","DOI":"10.1128\/AAC.03229-14","article-title":"Novel insights into the mechanism of inhibition of MmpL3, a target of multiple pharmacophores in Mycobacterium tuberculosis","volume":"58","author":"Li","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.ejmech.2014.08.066","article-title":"SAR analysis of new anti-TB drugs currently in pre-clinical and clinical development","volume":"86","author":"Poce","year":"2014","journal-title":"Eur. J. Med. Chem."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1128\/AAC.05270-11","article-title":"MmpL3 is the cellular target of the antitubercular pyrrole derivative BM","volume":"56","author":"Poce","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_127","doi-asserted-by":"crossref","unstructured":"Makobongo, M.O., Einck, L., Peek, R.M., and Merrell, D.S. (2013). In vitro characterization of the anti-bacterial activity of SQ109 against Helicobacter pylori. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0068917"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1128\/AAC.03972-14","article-title":"SQ109, a new drug lead for Chagas disease","volume":"59","author":"Li","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1021\/jm500131s","article-title":"Multitarget drug discovery for tuberculosis and other infectious diseases","volume":"57","author":"Li","year":"2014","journal-title":"J. Med. Chem."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.3389\/fmicb.2019.02417","article-title":"Rewiring of metabolic network in Mycobacterium tuberculosis During adaptation to different stresses","volume":"10","author":"Rizvi","year":"2019","journal-title":"Front. Microbiol."},{"key":"ref_131","doi-asserted-by":"crossref","unstructured":"Baughn, A.D., and Rhee, K.Y. (2014). Metabolomics of central carbon metabolism in Mycobacterium tuberculosis. Microbiol. Spectr., 2.","DOI":"10.1128\/microbiolspec.MGM2-0026-2013"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.tim.2011.03.008","article-title":"Central carbon metabolism in Mycobacterium tuberculosis: An unexpected frontier","volume":"19","author":"Rhee","year":"2011","journal-title":"Trends Microbiol."},{"key":"ref_133","doi-asserted-by":"crossref","unstructured":"Fieweger, R.A., Wilburn, K.M., and VanderVen, B.C. (2019). Comparing the metabolic capabilities of bacteria in the Mycobacterium tuberculosis Complex. Microorganisms, 7.","DOI":"10.3390\/microorganisms7060177"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"9819","DOI":"10.1073\/pnas.1000715107","article-title":"Gluconeogenic carbon flow of tricarboxylic acid cycle intermediates is critical for Mycobacterium tuberculosis to establish and maintain infection","volume":"107","author":"Marrero","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1111\/j.1365-2958.2006.05297.x","article-title":"Dual role of isocitrate lyase 1 in the glyoxylate and methylcitrate cycles in Mycobacterium tuberculosis","volume":"61","author":"Gould","year":"2006","journal-title":"Mol. Microbiol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"422","DOI":"10.2174\/157340609789117886","article-title":"Novel phthalazinyl derivatives: Synthesis, antimycobacterial activities, and inhibition of Mycobacterium tuberculosis isocitrate lyase enzyme","volume":"5","author":"Sriram","year":"2009","journal-title":"Med. Chem."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/ardp.200390004","article-title":"Relationship between the structure and antimycobacterial activity of substituted salicylanilides","volume":"336","author":"Waisser","year":"2003","journal-title":"Arch. Pharm. (Weinh.)"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.tube.2012.06.001","article-title":"Salicylanilide derivatives block Mycobacterium tuberculosis through inhibition of isocitrate lyase and methionine aminopeptidase","volume":"92","author":"Trejtnar","year":"2012","journal-title":"Tuberculosis"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1016\/j.bmc.2017.01.016","article-title":"Novel salicylanilides from 4,5-dihalogenated salicylic acids: Synthesis, antimicrobial activity and cytotoxicity","volume":"25","author":"Paraskevopoulos","year":"2017","journal-title":"Bioorganic Med. Chem."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1110\/ps.062300206","article-title":"The product complex of M. tuberculosis malate synthase revisited","volume":"15","author":"Anstrom","year":"2006","journal-title":"Protein Sci."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"6879","DOI":"10.1021\/bi2007299","article-title":"Kinetic and chemical mechanism of malate synthase from Mycobacterium tuberculosis","volume":"50","author":"Quartararo","year":"2011","journal-title":"Biochemistry"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1016\/j.chembiol.2012.09.018","article-title":"Structure-guided discovery of phenyl-diketo acids as potent inhibitors of M. tuberculosis malate synthase","volume":"19","author":"Krieger","year":"2012","journal-title":"Chem. Biol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1021\/ja063460m","article-title":"Structural criteria for the design of anion receptors: The interaction of halides with electron-deficient arenes","volume":"129","author":"Berryman","year":"2007","journal-title":"J. Am. Chem. Soc."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"4376","DOI":"10.1073\/pnas.0711159105","article-title":"Mycobacterial persistence requires the utilization of host cholesterol","volume":"105","author":"Pandey","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_145","doi-asserted-by":"crossref","unstructured":"Yam, K.C., D\u2019Angelo, I., Kalscheuer, R., Zhu, H., Wang, J.-X., Snieckus, V., Ly, L.H., Converse, P.J., Jacobs, W.R., and Strynadka, N. (2009). Studies of a ring-cleaving dioxygenase illuminate the role of cholesterol metabolism in the pathogenesis of Mycobacterium tuberculosis. PLoS Pathog., 5.","DOI":"10.1371\/journal.ppat.1000344"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1021\/jm00041a014","article-title":"6-Azasteroids: Structure-activity relationships for inhibition of type 1 and 2 human 5 alpha-reductase and human adrenal 3 beta-hydroxy-delta 5-steroid dehydrogenase\/3-keto-delta 5-steroid isomerase","volume":"37","author":"Frye","year":"1994","journal-title":"J. Med. Chem."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1016\/j.bmcl.2011.03.004","article-title":"Inhibition of the M. tuberculosis 3\u03b2-hydroxysteroid dehydrogenase by azasteroids","volume":"21","author":"Thomas","year":"2011","journal-title":"Bioorganic Med. Chem. Lett."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1084\/jem.20030846","article-title":"Transcriptional adaptation of Mycobacterium tuberculosis within macrophages: Insights into the phagosomal environment","volume":"198","author":"Schnappinger","year":"2003","journal-title":"J. Exp. Med."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1099\/mic.0.000604","article-title":"Loving the poison: The methylcitrate cycle and bacterial pathogenesis","volume":"164","author":"Dolan","year":"2018","journal-title":"Microbiology"},{"key":"ref_150","doi-asserted-by":"crossref","unstructured":"VanderVen, B.C., Fahey, R.J., Lee, W., Liu, Y., Abramovitch, R.B., Memmott, C., Crowe, A.M., Eltis, L.D., Perola, E., and Deininger, D.D. (2015). Novel inhibitors of cholesterol degradation in Mycobacterium tuberculosis reveal how the bacterium\u2019s metabolism is constrained by the intracellular environment. PLoS Pathog., 11.","DOI":"10.1371\/journal.ppat.1004679"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1128\/AAC.02293-13","article-title":"Energy metabolism and drug efflux in Mycobacterium tuberculosis","volume":"58","author":"Black","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"12393","DOI":"10.1038\/ncomms12393","article-title":"Turning the respiratory flexibility of Mycobacterium tuberculosis against itself","volume":"7","author":"Lamprecht","year":"2016","journal-title":"Nat. Commun."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/13\/9\/227\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:05:15Z","timestamp":1760177115000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/13\/9\/227"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,31]]},"references-count":152,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2020,9]]}},"alternative-id":["ph13090227"],"URL":"https:\/\/doi.org\/10.3390\/ph13090227","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,31]]}}}